Although currently prescribed antidepressants with actions mediated through alteration of monoaminergic transmission have been proven to be useful for the treatment of depressive and anxiety disorders, they are far from ideal due to their slow onset of action and low rate of responses. Although the brain monoamine systems have long been the focus of drug therapy for depression and anxiety disorders, current drug discovery has aimed at new molecular targets outside the monoamine systems to overcome these problems. Recent increase in understanding of the molecular mechanisms of depression and anxiety has provided alternative molecular targets for these disorders. In particular, receptors within the glutamate, γ-aminobutyric acid and neuropeptide systems provide a diversity of drug targets, and molecular biological and behavioral studies of these receptors have revealed the important roles they play in depression and anxiety. Here, we review recent patents and advances in research on these emerging molecular targets for the treatment of depression and anxiety, and discuss their advantages over currently used antidepressants and anxiolytics.
INTRODUCTION
Major depressive disorder and anxiety disorders are among the most prevalent forms of mental illness. In the United States, it is estimated that 21% of women and 13% of men will suffer major depressive disorder at some point in their lifetime, and that, together with anxiety disorders, more than 20% of the adult population will suffer from these conditions at some point in life.
All current antidepressant medications have stemmed from study of the mechanisms of serendipitously discovered agents, the tricyclic antidepressants (e.g., imipramine) and the monoamine oxidase inhibitors (e.g., iproniazid), which exhibit effects via modulation of monoamine neurotransmission. This study has led to the development of newer generation antidepressants, the selective serotonin reuptake inhibitors (SSRIs) and serotonin-and noradrenaline reuptake inhibitors (SNRIs), both of which are widely prescribed today. These agents have a less serious side effect profile than first-generation drugs, but are neither more efficacious nor rapidly acting than them. Although the large majority of individuals (~70%) with depression exhibit some improvement with antidepressant medication, only ~50% of all patients exhibit remission. Moreover, currently used antidepressants require 3-6 weeks for manifestation of significant therapeutic effects.
Although many patients with anxiety disorders have been successfully treated with benzodiazepines (BZDs) in short-*Address corresponds to this author at the Medicinal Pharmacology Laboratory, Medicinal Research Laboratories, Taisho Pharmaceutical Co., Ltd., 1-403 Yoshino-cho, Kita-ku, Saitama, Saitama 331-9530, Japan; Tel: +81-48-669-3089; Fax: +81-652-7254; E-mail: s.chaki@po.rd.taisho.co.jp term use, long-term use of BDZs have been shown to increase the risk of drug dependence. Moreover, the clinical effectiveness of BDZs is limited to generalized anxiety disorder and the acute phase of panic disorder, and they failed to improve symptoms in patients with obsessivecompulsive disorder [1] . It has recently been found that antidepressants such as SSRIs and SNRIs are more effective for most anxiety disorders than BDZs, and they have become first-line treatment for these disorders as well [2] . SSRIs are now widely used for panic disorder, post-traumatic stress disorder, and obsessive-compulsive disorder, and SSRIs such as paroxetine and SNRIs such as venlafaxine have been approved for the treatment of generalized anxiety disorder. However, these medications usually take several weeks to exhibit effects, as in the case of depression.
Many of the drawbacks of current medications for depression and anxiety are likely related to the mechanisms of action of these medications. To overcome these drawbacks, the focus of drug discovery research has therefore recently shifted to non-monoamine-based strategies. Apart from biogenic amine theory, alternative hypotheses regarding the origin of depression have recently provided the rationale for new strategies for the development of antidepressants and anxiolytics. Selective compounds based on new strategies are now available for testing in animal and human studies, and some encouraging results have been obtained with them.
In this review, we focus on some attractive and seemingly promising molecular targets for the treatment of depression and anxiety, and covers patents for compounds emerging from study of these targets.
GLUTAMATE
Glutamate is the major excitatory neurotransmitter in the brain, and is involved in a wide range of physiological processes in the central nervous system (CNS) including emotion, cognition, and motor function. Dysfunction of excitatory amino acid transmission may play a role in the etiology and pathophysiology of depression [3] . Indeed, it has been reported that a single intravenous dose of ketamine (a noncompetitive NMDA receptor antagonist) had rapid and prolonged antidepressant effects in depressed patients [4] . At present, glutamate receptors are classified into two major types: ionotropic glutamate receptors (iGluRs), in which the receptors have an ion channel structure, and metabotropic glutamate receptors (mGluRs), which are coupled to Gproteins [5] . IGluRs are also classified into N-methyl-Daspartate (NMDA), α-amino-3-hydroxy-5-methyl-isoxazole-4-propionate (AMPA) and kainate receptors [5] . MGluRs are classified into three groups based on their sequence homology, second messenger coupling and pharmacological characteristics [6] . Group I mGluRs include mGluR1 and mGluR5, which are coupled to phospholipase C, while both group II mGluRs (mGluR2, mGluR3) and group III mGluRs (mGluR4, mGluR6, mGluR7, mGluR8) are negatively coupled to adenyly cyclase activity. Of these, both group I and group II mGluR ligands as well as AMPA receptor potentiators have become the focus of much attention in recent years, based on findings concerning of their distribution in the brain and preclinical animal studies with selective ligands.
Group I mGluR Antagonists (mGluR1 Antagonists, mGluR5 Antagonists)
Both mGluR1 and mGluR5 are expressed in the brain regions related to emotion, whereas mGluR5 is more abundantly expressed throughout the cerebral cortex, hippocampus and limbic system [7] . The recent discovery of mGluR5 receptor selective antagonists has revealed important roles of mGluR5 in depression and anxiety. It has, for example, been reported that a selective and noncompetitive mGluR5 antagonist, MPEP (Fig. 1) , attenuated learning deficits in the passive avoidance paradigm in the rat olfactory bulbectomy model [8] and shortened immobility in the mouse tail suspension test [7, 9] , suggesting antidepressant-like potential. Moreover, MPEP has been demonstrated to exhibit anxiolytic effects in a variety of animal models of anxiety including tests involving the exploratory component, conflict component and stress component [7] [8] [9] , and these effects were also observed with a newly synthesized mGluR5 antagonist, MTEP (Fig. 1) [10] . The anxiolytic-like effects of mGluR5 antagonists appear to be of the same magnitude as those of the BDZs, but with improved side effect liabilities. The anxiolytic-like potential of mGluR5 antagonists is consistent with the finding for KO mice lacking mGluR5 of an anxiolytic-like phenotype in the stress-induced hyperthermia test [11] .
Unlike mGluR5 antagonists, the anxiolytic-like potential of mGluR1 antagonists has not been fully examined. It has recently been reported that JNJ16259685 (Fig. 2) , a selective and noncompetitive mGluR1 antagonist, exhibits anxiolytic effects in rodents in the conflict drinking test, but that these effects are task-dependent [12] . Likewise, anxiolytic effects were observed with another mGluR1 antagonist, LY456236 (Fig. 2) , although they were not as potent as those of mGluR5 antagonists and BDZs [13] . Of note, it has been reported that mGluR1 receptor antagonists disrupted hippocampal long-term potentiation and spatial learning [14] .
More than twenty patent applications presenting mGluR5 antagonists have been published from 2003 through 2005 (Fig. 1) . Many of compounds provided in the applications have two or more aromatic rings, which are connected by a heterocyclic ring or acetylene moiety.
In 2003 and 2004, a series of patent applications presenting mGluR5 antagonists were published by Merck (e.g. compounds (1) - (9)) . The compounds described in the applications have the same structural feature: a 5-membered heterocyclic ring (pyrrole, imidazole, pyrazole, triazole, tetrazole), substituted with other two aromatic rings at the 1 and 3 positions. One of the aromatic rings is a 2-pyridyl group, and the other is a substituted phenyl group. Merck also published mGluR5 antagonist-related applications presenting different types of compounds (e.g. compounds (10) and (11)) [24, 25] .
Compounds in patent applications from F. Hoffmann-La Roche AG contain an acethylene moiety functioning as a linker between two heterocyclic rings (compounds (12) - (15)) [26 -29] .
Compounds (16) - (20) [30 -34] are examples in applications from Euro-celtique, of compounds either having or not having an acethylene linker.
Applications from AstraZeneca exemplify compounds possessing various heteroaromatic rings (e.g. compounds (21)-(24)) [35] [36] [37] [38] . Compound (25) [39] and compound (26) [140] are examples in applications from Addex Pharmaceuticals and Novartis, respectively.
Group II mGluR Agonists and Antagonists
Group II mGluR is abundantly localized within forebrain regions, where it modulates glutamate transmission via presynaptic and postsynaptic mechanisms [41] . Forebrain areas that express group II mGluR include limbic structures that participate in the control of emotion. Thus, compounds acting on group II mGluRs may possibly modulate emotional states. This hypothesis is supported by the findings that oral administration of a selective group II mGluR agonist, LY354740 (Fig. 3) , showed anxiolytic-like effects in fearpotentiated startle in rats and elevated plus maze models in mice [42, 43] . LY354740 also produced anxiolytic-like effects in the Vogel test in rats and a four-plate test in mice [44] . Moreover, LY354740 has been reported to prevent lactate-induced panic-like response in panic-prone rats, as did alprazolam, a clinically effective anti-panic drug [45] . Thus, group II mGluR agonists might be effective for panic disorder, a severe and often debilitating condition among anxiety disorders. Unlike BDZs, LY354740 did not exhibit undesirable CNS side effects such as sedation, deficits in neuromuscular coordination, interaction with CNS depressants, memory impairement or change in convulsive threshold at the pharmacologically effective dosage. Clinical results with LY354740 and its prodrug LY544344 have demonstrated anxiolytic-like efficacy in a model of panic disorder (panic provocation induced by CO 2 challenge in subjects with panic disorder) [46] and in a fear-potentiated startle reflex paradigm in healthy volunteers [47] , although clinical trials have been suspended because of increased probability of epileptic seizures in rodents. However, new possibilities are being pursued with recently generated mGluR2 selective allosteric potentiators [48, 49] . Of note, significant in vivo anxiolytic and antipsychotic activities were confirmed with selective mGluR2 allosteric potentiators [48, 49] .
We recently found that group II mGluR antagonists exhibited antidepressant-like activity in behavioral despair models (forced swim test and tail suspension test) [50] , while LY354740, a group II mGluR agonist, did not exhibit antidepressant-like effects in these models [44] . Moreover, MGS0039 (Fig. 3) , a selective group II mGluR antagonist, increased progenitor cell proliferation in the hippocampus [51] and increased serotonergic transmission [52] , both of which are considered mechanisms of antidepressant-like activity. Consistent with these findings, it has been reported that LY341495 (Fig. 3) , another group II mGluR antagonist, attenuates anhedonia after nicotine withdrawal [53] , providing additional evidence for its antidepressant-like potential. Given that NMDA receptor antagonists including ketamine have been shown to increase glutamate release in the nucleus accumbens [54] and that KO mice lacking mGluR7 [55] , which function as autoreceptors, display an antidepressant phenotype, increase in glutamate release in certain brain regions may be a useful strategy of treatment of depression. Moreover, group II mGluR antagonists have been shown to be effective in the mouse marble burying test, an animal model predictive of obsessive-compulsive disorder [56] . In contrast, MGS0039, unlike group II mGluR agonists, exhibited no appreciable anxiolytic-like activity with acute administration in classical anxiety paradigms such as elevated plus-maze and social interaction [50] .
A few patent applications presenting mGluR2 agonists (e.g. compound (27) ) [57] and antagonists (e.g. compound (28) and (29)) [58, 59] have been published in [2003] [2004] [2005] (Fig. 3) . Compound (30) [60] has a glutamate-analogue moiety and compound (27) is a glutamate analogue presented as LY354740. In contrast, non-glutamate analogues were provided as mGluR2 antagonists by Hoffmann-La Roche (compound (28) and (29)) [58, 59] . They have aromatic rings in the structures, and their structural features differ considerably from those of LY341495 and MGS0039, both of which include a glutamate analogue. Compound (29) has been reported to have an IC 50 value of 1.2 nM for mGluR2. It is intriguing that both types of compounds, glutamate analogues and nonglutamate analogues, exhibit high affinities for mGluR2. Eli Lilly reported selective mGluR2 allosteric potentiators (e.g. 3-MPPTS) ( Fig. 3) , which exhibited in vivo activities [48] .
AMPA Receptor Potentiators
During the past several years, an emerging body of evidence has suggested that enhanced AMPA-mediated transmission may be responsible in part for the efficacy of antidepressants, and that stimulation of AMPA receptors may have antidepressant effects in preclinical animal models of depression. Chronic, but not acute, administration of antidepressants such as desipramine and paroxetine increased GluR1 and GluR2/3 levels in the membrane fractions of hippocampal extracts while not affecting levels in total extract [61] , indicating increased trafficking of AMPA receptors. In addition, fluoxetine increased phosphorylation of the AMPA receptor GluR1 subunit, which in turn increases the efficacy of AMPA receptors, and this has been suggested to play an important role in mediating the antidepressant effects of fluoxetine [62] . Thus, these findings suggest that enhancement of AMPA-mediated transmission may play a role in the neuronal mechanisms responsible for the efficacy of antidepressants.
It has been reported that AMPA receptor potentiators such as LY392098 (Fig. 4) [63] , LY404187 (Fig. 4) [64] and LY451646 (an active isomer of LY404187) [65] exhibit antidepressant-like activity in the forced swim test and tail suspension test without affecting motor activity. Moreover, it was reported that Ampakines, which are AMPA receptor potentiators, exhibited antidepressant effects during the 1 st week of treatment, while fluoxetine exerted effects after 2 weeks of treatment in a rat submissive behavior model [66] , suggesting faster onset of action, compared to current medication.
It has been found that an AMPA potentiator increases brain-derived neurotrophic factor (BDNF) mRNA expression in the hippocampus [67] and increases adult hippocampal neurogenesis [68] . Converging lines of evidence suggest that BDNF and hippocampal neurogenesis may be a pivotal downstream mediator of antidepressant effects [69] . Chronic, but not acute, treatment with a structurally diverse group of antidepressants as well as electroconvulsive shock have been reported to elevate hippocampal levels of mRNA encoding BDNF as well as hippocampal neurogenesis [69, 70] , and BDNF has been found to exhibit antidepressant-like activity in animal models [71] . Interestingly, an AMPA receptor potentiator has been reported to tend to increase neurogenesis even after a single injection [68] , consistent with the faster onset of action observed in the behavioral study [66] .
Several patent applications providing AMPA receptor potentiators have been published by Les Laboratories Servier (Fig. 4) , e.g. compounds (31)- (36)) [72] [73] [74] [75] [76] [77] and Neurosearch (compounds (37)) [78] . Most of the compounds have two or three ring systems that contain a sulfonyl amide moiety. Side chains attached to the ring systems are diverse and may thereforeplay key roles in determining the degree to which AMPA receptor activity is potentiated.
GABA
γ-Aminobutyric acid (GABA) is the most abundant inhibitory neurotransmitter in the mammalian brain, where it is widely distributed. It has recently been suggested that major depressive disorder as well as anxiety disorders are associated with dysfunction of GABAergic transmission [79] . There are two major receptor subtypes of GABA: ionotropic GABA A receptors and metabotropic GABA B receptors [80] . The involvement of GABA A receptors in anxiety disorders has been well investigated and established. However, recent studies using selective GABA B ligands (both antagonists and positive modulators) and KO mice lacking functional GABA B receptors have demonstrated important roles of the GABA B receptor subtype in depression and anxiety.
GABA B Receptor Positive Allosteric Modulators and Antagonists
GABA B receptors are abundant in the brain, particularly, in the limbic system, suggesting that they play roles in regulation of mood and affect. It has been reported that functional GABA B receptors exist as heterodimers of two subunits, GABA B(1) and GABA B (2) . The findings that GABA B -mediated responses are blunted in mice lacking either GABA B(1) or GABA B(2) [81] confirm that heterodimerization of GABA B(1) and GABA B (2) is necessary for receptor function. It has been found that a GABA B receptor positive modulator, GS39783, exhibits anxiolytic effects in several models such as the elevated plus-maze, elevated zero maze, light/dark box and stress-induced hyperhermia without causing the unwanted side effects observed with BDZs [82, 83] . Thus, GABA B receptor positive modulators may represent a novel class of anxiolytics with a safety profile superior to that of BDZs. In accordance with these observations, GABA B(1) -/-mice have been reported to be more anxious than wild type mice [83] .
In contrast, mice with disrupted GABA B(1) display an antidepressant-like phenotype, with decreased immobility in the forced swim test, suggesting that blockade of GABA B receptors may serve as a novel strategy for the treatment of depression [83] . In support of this, it has been reported that the GABA B receptor antagonists CGP56433A (Fig. 5) and CGP36742 (Fig. 5) exhibit antidepressant effects in the forced swim test and the learned helplessness test, respectively [83] [84] [85] . Moreover, it has been reported that, in the forced swim test, GABA B receptor antagonists increased swimming behavior, as observed with SSRIs, and serotonergic transmission has been suggested to play a role in mediating the antidepressant effects of GABA B receptor antagonists [85] . Given that GABA B receptors play a role in inhibiting the firing of serotonin-containing cells in the dorsal raphe nucleus [86] , interaction with the serotonergic system may account for the antidepressant effects of GABA B receptor antagonists. Interestingly, it has also been reported that GABA B receptor antagonists increase BDNF mRNA in the brain, including the hippocampus [87] , which may contribute to antidepressant effects [71] .
In 1989, an application for 3-aminopropyl phosphinic acids derivatives as GABA B receptor antagonists was published by Ciba-Geigy Corporation. Few applications for GABA B antagonists were published for about the next ten years. In 2001 and 2002, however, a few applications presenting new types of 3-aminoprpyl phosphinic acids for GABA B antagonists were published by AstraZeneca (Fig. 5) , compounds (38) - (40)) [88 -90] . The claimed structures in the applications have a hydrogen, methyl, or mono-, di-or tri-fluoro methyl group on the phosphorus atom, differentiating them from those in previous patents. No biological data were provided in these applications.
NEUROPEPTIDES
It has recently come to be recognized that stress may be the primary cause of depression and anxiety disorders. In the brain, short-chain amino acid neurotransmitters, the neuropeptides, have been suggested to play a pivotal role in stress responses. These peptides are locally produced in particular brain regions and their expression and release are altered upon exposure to stress. With recent advances in cloning of each receptor subtype gene, identification of selective nonpeptidic compounds for each receptor, as well as behavioral and neurochemical analyses using mice with targeted gene mutations, the roles of neuropeptides and their receptors in stress responses and emotional states have been delineated, and many neuropeptide systems have emerged as attractive targets in the treatment of stress-related disorders such as depression and anxiety [91] . Of these, tachykinins, corticotropin-releasing factor (CRF) and arginine vasopressin (AVP) have been well studied as regards their relationships with stress-related disorders, and clinical studies with selective antagonists for these peptide receptors are ongoing. In addition to these peptidergic systems, the list of neuropeptide systems implicated in stress responses and proposed as therapeutic targets for depression and anxiety disorders is growing.
Tachykinin Receptor Antagonists (NK 1 Receptor Antagonists, NK 2 Receptor Antagonists)
The tachykinins are a family of closely related peptides, mainly consisting of substance P, neurokinin A and neurokinin B. To date, three tachykinin receptor subtypes, NK 1 , NK 2 , NK 3 , have been identified [92] , all three of which are distributed in the CNS through with different levels of expression [92] . Of these, both NK 1 (the receptor for substance P) and NK 2 (the receptor for neurokinin A) receptors have been proposed to play important roles in depression and anxiety.
Selective nonpeptidic antagonists for each of these receptors have been developed, and their antidepressant and anxiolytic effects have been demonstrated. Although there are marked species differences in the pharmacological properties of NK 1 receptors, behavioral studies in species (guinea pigs, gerbils) whose pharmacological and molecular properties are closer to those in humans have provided evidence that NK 1 receptor antagonists exhibit antidepressant and anxiolytic-like activities in numerous animal models [93] [94] [95] [96] . Consistent with the results obtained with NK 1 receptor antagonists, KO mice lacking NK 1 receptors exhibited reduced anxiety and depressive-like behaviors [97] . Moreover, antidepressant efficacy was demonstrated in patients with major depressive disorder in placebo-controlled trials with two highly selective NK 1 receptor antagonists, aprepitant (Fig. 6) and L-759274 [93, 94] . Although treatment with aprepitant in Phase II trials resulted in improvements in depression and anxiety symptoms that were quantitatively comparable to those with SSRIs and significantly greater than those with placebo, Merck recently announced discontinuation of the Phase III clinical development of aprepitant due to lack of demonstrable efficacy for depression.
Likewise, selective NK 2 receptor antagonists including SR48968 (Fig. 7) exhibit antidepressant and anxiolytic effects in several animal models [99, 100] such as the force swim test, maternal separation-induced vocalization and elevated plus-maze task. Interestingly, SR48968 increased the expression of cAMP response element binding (CREB) protein mRNA in the hippocampus after repeated administration [100] . Moreover, an NK 2 receptor antagonist exhibited anxiolytic effects in the marmoset human intruder response test [101] . SR48968 is currently in Phase III clinical trials for depression.
In 2004 and 2005, more than ten patent applications providing NK 1 receptor antagonists have been published (Fig. 6) . Notably, many of the representative compounds presented in the applications have a common structural element, a 3,5-bistrifluoromethyl phenyl group, although their frameworks differ markedly one another. Six applications from Janssen Pharmaceutica provided a series of piperazines substituted with two cyclic amines, and most of the examples in the applications included the 3,5-bistrifluoromethyl phenyl group (e.g. compounds (41) - (46)) [102 -107] . The affinities for NK 1 receptors were presented for the representative compounds ( [112] , applications related to NK 1 antagonists have recently been published, including many representative compounds with the 3,5-bistrifluoromethyl phenyl group. However, biological data are presented for only a few of these compounds ( Table 1) . Solvay Phamaceutical indicated a pKi value (9.2) for compound (51) , and Schering Corporation indicated that the Ki value for NK 1 receptors of compound (48) was 0.3 nM. Applications from Nikem Research (e.g. compound (52)) [113] and AstraZeneca (e.g. compounds (53) and (54) (Fig. 7) . Example compounds in the applications have a quinoline ring, which is substituted with an aminocarbonyl group, a piperazinomethyl group, and an aromatic ring at the 4, 3, and 2 position, respectively (e.g. compounds (55) - (58)) [116 -119] . They noted that the applications contained NK 2 and NK 3 receptor antagonists.
CRF 1 Receptor Antagonists
CRF is a 41-amino acid peptide originally purified from ovine hypothalamus [120] . It has been reported that CRF plays a crucial role in adaptive responses to stress, as well as in the mediation of depressive and anxiety-like behavior [121] . It has been demonstrated that patients with major depressive disorder or post-traumatic stress disorder have increased cerebrospinal fluid levels of CRF [122] . Moreover, a blunted adrenocorticotropin (ACTH) response to i.v. injection of CRF has been found in patients with depression, anorexia nervosa and post-traumatic stress disorders [123, 124] . CRF exerts effects through two receptor subtypes, CRF 1 and CRF 2 , both of which are Gs coupled GPCRs [125] , while the CRF 1 receptor has been emphasized to play a role in depressive-and anxiety-like behaviors. A number of nonpeptidic CRF 1 receptor antagonists have been introduced, and some of which, including CP-154,526 (Fig. 8) , DMP696 ( Fig. 8) and SSR125543A (Fig. 8) , have demonstrated antidepressant and anxiolytic effects in numerous rodent models, in particular those involving highly stressful conditions [126] . Moreover, we have recently reported that R278995/CRA0450 (Fig. 8) exhibits antidepressant-like activity in the learned helplessness paradigm even with single administration, suggesting early onset of action [127] . In addition to rodent models, it has been demonstrated that antalarmin reduces anxiety-like behaviors in social stress models in a non-human primate [128] . Moreover, the results of the first open-label, dose-escalating trial with R121919 ( Fig. 8 ) in 20 patients with major depressive disorder revealed significant reduction in both depression and anxiety scores [129] . In a Phase II trial, R121919 was found to be safe and well-tolerated, although it produced slight elevation of liver enzyme levels [129] .
Approximately twenty patent applications presenting new CRF 1 receptor antagonists have been published in 2004 and 2005 (Fig. 8) . All of the CRF 1 receptor antagonists provided in these applications have mono-or di-heterocyclic moieties in the central part of their structure. Various types of heterocyclic rings are used for this part: mono-heterocyclic rings such as pyrimidine and pyrazine, and di-heterocyclic 
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ring systems such as triazolopyrazine, pyrrolopyrimidine, pyrrolopyrimidine and others. Most of the presented compounds have an aromatic ring next to the nitrogen atom in the central heterocyclic ring and a hydrophobic group on the side opposite the position where the aromatic ring is attached.
Applications from Neurogen Corporation & Aventis Pharmaceuticals Inc. include compounds with a diheterocyclic ring system containing a pirazine ring (e.g. compounds (59) and (60)) [130, 131] . Compound (61) [132] and its analogues exemplified in an application from F. Hoffman-La Roche have a unique spiro-ring system which could differentiate them from other CRF 1 receptor antagonists. They also made applications for compounds containing di-heterocyclic ring systems (e.g. compounds (62) - (63)) [133, 134] . Compounds (64) and (65) [135, 136] , in applications from SB Pharmco Puerto Rico Inc. & Neurocrine Biosciences Inc., have a pyrazole ring substituted on their scaffold ring system. In 2004, nine international applications from Pharmacia & Upjohn Company were published. The compounds they published included diheterocyclic ring systems (e.g. compounds (66) - (70)) [137 -141] and mono-heterocyclic rings (e.g. compounds (71) - (74)) [142 -145] . Compounds (75) [146] and (76) [147] were exemplified in the applications from Ono Pharmaceutical Co., Ltd. and Taisho Pharmaceutical Co., Ltd., respectively, and included di-heterocyclic ring systems. Compounds exemplified in an application from Novartis AG (e.g. compound (77)) [148] , each have a bicyclic heteroaromatic ring such as a benzothiaziazole, a unique structural feature. An application from Glaxo Group Limited includes pyrazole-substituted pyrrolopyridine derivatives (e.g. compound (78)) [149] which are similar to CRF 1 receptor antagonists published by SB Pharmco Puerto Rico Inc. & Neurocrine Biosciences Inc. described above.
Few biological data are presented in these applications ( Table 1) .
AVP Receptor Antagonists (V 1a Receptor Antagonists, V 1b Receptor Antagonists)
AVP is a cyclic nonapeptide, and has been considered the principal factor in the regulation of ACTH release from the pituitary [150] . In addition to its involvement in the regulation of hypothalamic-pituitary-adrenal (HPA) axis activity, AVP is believed to play a role in regulation of mood. Indeed, it has been reported that both plasma concentration of AVP and the number of AVP immunoreactivity in the paraventricular nucleus (PVN) are higher in depressed patients than in healthy controls [151, 152] . AVP exerts effects via three receptor subtypes, V 1a , V 1b and V 2 receptors [153] . Of these, V 1a and V 1b receptors have been reported to be involved in emotional processes [154, 155] , while the V 1b receptor is a focus of current interest based on a series of studies using a nonpeptidic and selective V 1b receptor antagonist, SSR149415 (Fig. 9) . It has been reported that SSR149415 exhibits antidepressant-and anxiolytic-like activities in a variety of rodent models of depression and anxiety, with more pronounced effects in models involving stressful situations [156, 157] , and reverses stress-induced alterations in release of norepinephrine and ACTH [157] . It has also been reported that not only regulation of HPA axis activity but extrahypothalamic effects are involved in the antidepressant effect of the V 1b receptor antagonist [158] . Moreover, repeated administration of V 1b receptor antagonist, like CRF 1 receptor antagonist and fluoxetine, reverses stress-induced reduction of adult hippocampal neurogenesis, which has been considered one of the causes of depression [39] , in a mouse chronic mild stress model, while neither a V 1b receptor antagonist nor a CRF 1 receptor antagonist had significant effects in non-stressed animals [159] .
In addition to V 1b receptor antagonists, it has recently been reported that JNJ-17308616, a V 1a receptor antagonist, exhibits anxiolytic effects in some models of anxiety including the elevated plus-maze and separation-induced vocalization [160] , raising the possibility that V 1a receptors could be another attractive target in the treatment of anxiety disorders.
In 2004 and 2005, several international patent applications providing V 1a receptor antagonists and V 1b receptor antagonists have been published (Fig. 9) . Compound (79) [161], an example in the application from Janssen Pharmaceutica, was stated to exhibit V 1a and V 2 receptor antagonist activity. Another application for V 1a receptor antagonists from Pfizer presented triazole derivatives (e.g. compound (80)) [162] . Affinities for V 1a receptors of representative compounds among the examples in the application were presented. The Ki value of compound (80) was reported to be 4.5 nM. Applications for novel V 1b receptor antagonists have recently been published by three companies, Sanofi-Synthelabo (e.g. compound (81)) [163] , Abbott GMBH (e.g. compound (82)) [164] and Taisho Pharmaceutical Co., Ltd (e.g. compound (83)) [165] . The claimed structures in the three applications exhibit little diversity and have a quite similar framework, 1,3-dihydroindole-2-one, which probably originated from SSR149415. Despite their similarity of structure, the compounds in each application have unique structural characteristics. Compounds published by Abbott GMBH have heterraromatic rings as substituents on the framework, these exemplified by Taisho have a fluorine atom on the proline moiety, and these from Sanofi-Synthelabo have an acyloxy moiety on the proline moiety.
MCH1R Antagonists
Melanin-concentrating hormone (MCH) is a cyclic 19-amino acid peptide originally isolated from salmon pituitary [166] . In mammals, MCH is produced predominantly by neurons in the lateral hypothalamus and zona incerta with extensive projections throughout the brain [167] , and exerts numerous physiological effects including increase in food intake and production of depressive and anxiety-like behaviors [168, 169] . Two receptor subtypes have been reported, MCH1R and MCH2R, both of which belong to the GPCR superfamily [170] . Emerging lines of evidence have suggested that MCH1R mediates not only regulation of feeding behavior but also regulation of emotional states. MCH1R is densely expressed in the nucleus accumbens shell, a brain region involving motivation and reward, and it has been reported that local injection of MCH into the nucleus accumbens shell displays a depressive phenotype in the forced swim test, while local injection of an MCH1R antagonist exhibits antidepressant effects [168] . It has also been reported that MCH1R is expressed in dynorphinpositive medium spiny neurons in the nucleus accumbens shell [168] and may negatively regulate dopaminergic activity in this region [171] , which may explain in part the mechanism of MCH-induced depressive behavior. In addition to regulation of dopaminergic activity in the nucleus accumbens, MCH1R has been reported to be densely distributed in the PVN of hypothalamus, where it regulates HPA axis activity through CRF secretion [172] . Consistent with the above findings, it has been reported that systemic administration of nonpeptidic MCH1R antagonists such as ATC0175 (Fig. 10) and SNAP-7941 (Fig. 10) has antidepressant and anxiolytic effects in a variety of rodent models of depression and anxiety [173, 174] . These MCH1R antagonists have been reported to be devoid of sedative and motor effects [173, 174] . Moreover, it was reported that another nonpeptidic MCH1R antagonist, SNAP-94847 exerted antidepressant effects in a chronic mild stress paradigm faster than citaropram, suggesting faster onset of action than SSRIs [175] .
In 2004 and 2005, more than 30 patent applications presenting MCH1R antagonists have been published by over 10 pharmaceutical companies (Fig. 10) . Most compounds provided in the applications have two or more aromatic rings and some basic amines.
Recent applications published by Synaptic Pharmaceutical Co. include a variety of MCH1R antagonists, most of which have a cyclic amine and two or more aromatic rings (e.g. compounds (84) - (87)) [176 -179] . Compounds (88) -(90) [180 -182] heteroaromatic rings in each molecule (e.g. compounds (91) - (95)) [183 -187] . Compounds (96) -(100) [188 -192] , which have piperidine-or piperazine-based structures, were published in applications by Schering Co. Compounds (101) -(102) [193, 194] , (103) -(104) [195, 196] , (105) -(106) [197, 198] and (107) -(108) [199, 200] were published by Amgen, Aventis Pharma Deutschland GMBH, 7TM Pharma A/S, and Neurocrine Biosciences, respectively. Compounds (109) -(114) [201 -206] were published by six individual companies.
As can be seen, many applications related to MCH1R antagonists have recently been published by many pharmaceutical companies, suggesting that MCH1R is believed to have strong potential for clinical use.
Biological data for several of these compounds have been presented (Table 1) , and many of these compounds demonstrate nanomolar or subnanomolar affinities for MCH1R.
MC 4 Receptor Antagonists
Melanocortins (ACTH and α-, β-and γ-melanocytestimulating hormone (α-, β-and γ-MSH)) are derived from proopiomelanocortin (POMC) by enzymatic processing, and participate in a wide range of physiological functions. The melanocortins have 5 subtypes of receptors (MC 1 -MC 5 ), all of which are coupled to Gs [207] . In the brain, MC 3 and MC 4 receptors are mainly expressed, with little expression of MC 5 receptor. Of these, it has been shown that MC 4 receptor plays a role in regulation of emotion and stress responses. It has been reported that MC 4 receptor agonists induce grooming behavior in rats, and that the MC 4 receptor antagonist SHU9119 attenuates MC 4 receptor agonist-induced grooming as well as novelty-induced grooming [208] . Moreover, the MC 4 receptor has been suggested to play a role in the regulation of HPA axis activity [209] , presumably through regulation of CRF secretion in the PVN of hypothalamus. In addition to the PVN, it has been reported that MC 4 in the amygdala may be involved in anxiety-like behavior [210] . An MC 4 receptor antagonist, MCL0129 (Fig.  11) , has been found to exhibit antidepressant and anxiolytic effects in several animal models [211] . MCL0129 has been demonstrated not to affect locomotor activity, rotarod performance and hexobarbital-induced anesthesia [211] , suggesting that it may not have CNS side effects observed with BDZs. Anxiolytic and anti-stress effects were observed with another selective peptidomimetic MC 4 receptor antagonist, MCL0020 (Fig. 11) [212] . Interestingly, MCL0129 exerted antidepressant effects after just a single administration in a learned helplessness paradigm [211] , while fluvoxamine exhibited this effect only after subchronic administration, indicating that MCL0129 has a rapid onset of action.
Recent applications from Myocontract (e.g. compound (115)) [213] , The Proctor & Gamble Company (e.g. compound (116)) [214] and Neurocrine Bioscience (e.g. compounds (117) and (118)) [215, 216] exemplify MC 4 receptor ligands that include a phenylalanine moiety (Fig.  11) . By contrast, compounds applied for by Millennium Pharmaceuticals have no amino acid moiety (compound (119)) [217] . Most of the applications do not indicate whether their compounds have an agonist or antagonist activity. Only a few applications provided biological data for the exemplified compounds ( Table 1) .
CURRENT & FUTURE DEVELOPMENTS
During the past decade, apart from biogenic amines, a variety of novel therapeutic targets have emerged for the treatment of depression and anxiety. With the development of novel pharmacological and genetic tools, the importance of these targets has been delineated. They include receptor subtypes within the glutamate, GABA and neuropeptide systems.
Based on the clinical observation that both glutamatergic and GABAergic transmission is impaired in depressed patients, and that ketamine, an NMDA receptor antagonist, exhibits antidepressant effects with acute administration, manipulation of these transmitter systems has come to be of interest. Because many compounds acting on either the glutamatergic or GABAergic system have serious side effects, attention has shifted to newer receptor subtypes (e.g. metabotropic receptors) to reduce unwanted side effects and to enhance efficacy.
Given that stress is considered a common primary cause of both depressive and anxiety disorders, stress-related neuropeptides and their receptors, in particular, those expressed in the hypothalamic nuclei, are attractive therapeutic targets for both disorders. In fact, most neuropeptide receptor ligands have been reported to be effective in animal models of both depression and anxiety, and they are more efficacious in models involving highly stressful situations, which may reflect etiology of these disorders. With recent identification of endogenous ligands for orphan GPCRs (most of which turned out to be neuropeptides) and elucidation of their physiological functions, the number of candidate neuropeptides on the list of possible therapeutic targets is increasing.
Although the outcome of a Phase III study with an NK 1 receptor antagonist (Aprepitant) was disappointing, it would be premature to judge the importance of non-monoaminebased treatment, and currently there are several compounds being tested for efficacy in clinical trials, with some encouraging results. Indeed, an NK 2 receptor antagonist is in a Phase III study for depression, and a group II mGluR agonist and a CRF 1 receptor antagonist have been found to be effective for anxiety disorder and major depressive disorder, respectively, in early proof-of-concept human studies.
Recently, it has been proposed that changes in intracellular events and subsequent neuronal networks are pivotal factors in the exertion of antidepressant effects. These include increases in expression of BDNF, CREB and eventually in neurogenesis in the hippocampus. The molecules controlling these events may be future targets for the treatment of depression and anxiety disorders.
